CD274 and non-small cell lung carcinoma: A meta-analysis involving 12 randomized clinical trials encompassing 6,932 patients with locally advanced NSCLC who received PD-1/PD-L1 inhibitors indicated that individuals with high PD-L1 expression levels exhibited longer PFS, OS, and overall response rate (ORR) in comparison to those with low PD-L1 levels (37).